Size-Tunable Immune Activation Particles for Efficient T Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for in vitro T cell activation, such as magnetic microbeads and plate-bound methods, are inefficient and can cause undesirable immune reactions, requiring billions of cells and posing risks.
Innovation Solution
Synthetic particles with immune co-stimulatory biomolecules, such as those activating 4-1BB, OX40, and CD28 receptors, are used to activate immune cells, potentially replacing traditional methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If magnetic microbeads or plate-bound methods are used for T cell activation, then T cell activation can be achieved, but the methods are inefficient and require billions of cells
Solution Approach 1:
The patent modifies the physical and chemical parameters of activation particles, including size (1-40 μm), surface charge density, and biomolecule composition (CD3, CD28, ICOS, 4-1BB, OX40 ligands). These parameter changes enable enhanced T cell activation efficiency with fewer cells required, directly addressing the productivity-quantity contradiction
Solution Approach 2:
The invention uses composite particles comprising multiple immune-stimulating biomolecules (CD3 antibody, CD28 ligand, ICOS ligand, 4-1BB ligand, OX40 ligand) combined on a single particle or in controlled mixtures. This composite approach synergistically enhances activation efficiency while reducing the total cell quantity needed compared to traditional single-component methods
2Productivity
If traditional activation methods are used, then T cell expansion can be achieved, but there is risk of undesirable immune reactions
Solution Approach 1:
The patent creates synthetic copies of immune cell surfaces by coating particles with specific biomolecules (CD3, CD28, ICOS, 4-1BB, OX40 ligands) that replicate the signaling functions of actual antigen-presenting cells. These synthetic copies provide controlled, predictable activation without the variability and adverse reactions associated with allogeneic feeder cells or viral transduction methods
Solution Approach 2:
The activation particles are designed as disposable, non-living synthetic objects that can be easily manufactured, standardized, and discarded after use. This eliminates the risks associated with living cell-based methods (viral contamination, donor variability, immune reactions to feeder cells) while maintaining effective T cell expansion capability
3Productivity
If current activation standards are used, then T cell stimulation can be achieved, but the process is inefficient and time-consuming
Solution Approach 1:
The patent merges multiple co-stimulatory signals (CD3, CD28, ICOS, 4-1BB, OX40) onto single particles or controlled mixtures, enabling simultaneous delivery of all necessary activation signals to T cells. This consolidation eliminates the need for sequential or parallel separate treatments, significantly reducing activation time while maintaining high productivity
Solution Approach 2:
The activation particles are pre-engineered with optimized combinations of biomolecules and physical properties before use. This preliminary preparation ensures that when particles contact T cells, all activation signals are immediately available, eliminating delays associated with sequential addition of reagents or waiting for cellular processing steps
Data Source
AI summary
The present disclosure provides synthetic biomolecule presenting particles for immune cell activation.